"Chemokine CCL5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CC-type chemokine that is a chemoattractant for EOSINOPHILS; MONOCYTES; and LYMPHOCYTES. It is a potent and selective eosinophil chemotaxin that is stored in and released from PLATELETS and activated T-LYMPHOCYTES. Chemokine CCL5 is specific for CCR1 RECEPTORS; CCR3 RECEPTORS; and CCR5 RECEPTORS. The acronym RANTES refers to Regulated on Activation, Normal T Expressed and Secreted.
| Descriptor ID |
D018946
|
| MeSH Number(s) |
D12.644.276.374.200.110.250 D12.776.467.374.200.110.250 D23.125.300.110.250 D23.469.200.110.250 D23.529.374.200.110.250
|
| Concept/Terms |
Chemokine CCL5- Chemokine CCL5
- CCL5, Chemokine
- RANTES Protein, T-Cell
- RANTES Protein, T Cell
- T-Cell RANTES Protein
- CCL5 Chemokine
- Chemokine, CCL5
- RANTES
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CCL5".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CCL5".
This graph shows the total number of publications written about "Chemokine CCL5" by people in this website by year, and whether "Chemokine CCL5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 2 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CCL5" by people in Profiles.
-
RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson's disease. Neurobiol Dis. 2019 12; 132:104575.
-
Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes. Exp Dermatol. 2018 12; 27(12):1322-1327.
-
Induction of Adaptive Immunity Leads to Nigrostriatal Disease Progression in MPTP Mouse Model of Parkinson's Disease. J Immunol. 2017 06 01; 198(11):4312-4326.
-
Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease. J Biol Chem. 2016 07 15; 291(29):15267-81.
-
Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8(+) T cells in the nigra of hemiparkinsonian monkey. Neuroscience. 2015 Aug 27; 302:36-46.
-
Chemokine analogues show suitable stability for development as microbicides. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):472-6.
-
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol. 2007 Sep; 14(9):1102-7.
-
Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection. J Acquir Immune Defic Syndr. 2007 May 01; 45(1):9-19.
-
Differences in HIV replication in CD4+ lymphocytes are not related to beta-chemokine production. AIDS Res Hum Retroviruses. 1998 Nov 01; 14(16):1407-11.
-
Chemokines are present in the genital tract of HIV-seropositive and HIV-seronegative women: correlation with other immune mediators. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 15; 18(5):454-9.